Home › Research › Treatments
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism
Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study Group.. Neurology, 2007-04-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Methods Multicenter randomized, double-blind, placebo-controlled parallel groups clinical trial involving 40 patients with dementia with Lewy bodies (n = 23), Parkinson disease (PD) with dementia (n = 9), or Alzheimer disease with parkinsonian features (n = 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified PD Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment. Results No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning. Conclusions Quetiapine was well-tolerated and did not worsen parkinsonism. Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating agitation or psychosis in patients with dementia and parkinsonism. These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients.
What this study adds
Evidence grade: High
This is a trial of 23 participants. In this small trial, quetiapine did not show significant benefit for agitation or psychosis in patients with dementia and parkinsonism, though it was generally well tolerated and did not worsen parkinsonism. The authors note the trial had limitations including a large placebo effect and inadequate dosage.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kurlan, R., Cummings, J., Raman, R., Thal, L., & Alzheimer's Disease Cooperative Study Group. (2007). Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. https://doi.org/10.1212/01.wnl.0000260060.60870.89
Vancouver
Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007. doi:10.1212/01.wnl.0000260060.60870.89. PMID: 17452579.
BibTeX
@article{kurlan2007-17452579,
author = {Kurlan, R. and Cummings, J. and Raman, R. and Thal, L. and {Alzheimer's Disease Cooperative Study Group}},
title = {{Quetiapine for agitation or psychosis in patients with dementia and parkinsonism}},
journal = {Neurology},
year = {2007},
doi = {10.1212/01.wnl.0000260060.60870.89},
pmid = {17452579},
url = {https://doi.org/10.1212/01.wnl.0000260060.60870.89}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results No significant differences in the primary or secondary outcome measures of efficacy were observed.
- Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning.
- These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients.
Why it matters
In this small trial, quetiapine did not show significant benefit for agitation or psychosis in patients with dementia and parkinsonism, though it was generally well tolerated and did not worsen parkinsonism. The authors note the trial had limitations including a large placebo effect and inadequate dosage.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants23
- Evidence strengthHigh
How this study scored 70/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 23 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 225 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.7 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 4 / 6 | Cited 8.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Leon J. Thal: h-index 90 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Rochester Medicine: institution h-index 953 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17452579) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.